amlexanox has been researched along with Alloxan Diabetes in 1 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, P | 1 |
| Sun, X | 1 |
| Liao, Z | 1 |
| Yu, H | 1 |
| Li, D | 1 |
| Shen, Z | 1 |
| Glass, CK | 1 |
| Witztum, JL | 1 |
| Saltiel, AR | 1 |
1 other study available for amlexanox and Alloxan Diabetes
| Article | Year |
|---|---|
The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.
Topics: Aminopyridines; Animals; Atherosclerosis; Bile Acids and Salts; Diabetes Mellitus, Experimental; Hum | 2022 |